Hidden reservoir of resistant parasites: the missing link in the elimination of falciparum malaria by unknown
OPINION Open Access
Hidden reservoir of resistant parasites: the
missing link in the elimination of
falciparum malaria
Rashad Abdul-Ghani1,2*, Mohammed A. K. Mahdy1,2, John C. Beier3 and Leonardo K. Basco4
Abstract
Background: To successfully eliminate malaria, an integrated system that includes a number of approaches and
interventions—aimed at overcoming the threat of antimalarial drug resistance—is required. Significant progress has
been made in reducing malaria incidence through large-scale use of artemisinin-based combination therapies and
insecticide-treated nets. To consolidate these gains, attention should be paid to the missing links in the elimination
of malaria. One of these gaps is the residual reservoir of submicroscopic resistant parasites, which remains after case
management or other control measures have been carried out. Therefore, the present opinion piece highlights the
importance of exploring the role that submicroscopic resistant parasites could play in hindering malaria elimination
by allowing the persistence of transmission, particularly in areas of low transmission or in the pre-elimination and/or
elimination phase.
Discussion: If malaria elimination interventions are to be effective, the relative role of the hidden reservoir of
resistant parasites needs to be assessed, particularly in regions that are low-transmission settings and/or in
pre-elimination and/or elimination phases. Various ongoing studies are focusing on the role of submicroscopic
malaria infections in malaria transmission but overlook the possible build-up of resistance to antimalarial drugs
among submicroscopic parasite populations. This is an important factor as it may eventually limit the effectiveness of
malaria elimination strategies.
Conclusions: An evidence-based estimation of the “true” reservoir of resistant parasites can help target the existing
and emerging foci of resistant parasites before they spread. Emergence and spread of artemisinin-resistant Plasmodium
falciparum malaria in Southeast Asia underline the need to contain drug resistance.
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Background
Globally, countries and regions affected by malaria are
devoting efforts to gradually eliminate it for good. Since
1998, great strides have been made in the fight against
malaria with the launch of the globally coordinated ini-
tiative, the Roll Back Malaria Partnership, by the World
Health Organization (WHO), the United Nations (UN)
Children’s Fund, the UN Development Programme, and
the World Bank [1]. The UN’s latest Millennium Devel-
opmental Goals Report raises hopes as it documents a
drop in the overall rates of global malaria incidence and
mortality by about 37 and 58%, respectively, as well as
the prevention of over six million deaths, between 2000
and 2015 [2]. The global decrease in the malaria burden
is mainly attributed to the introduction of artemisinin-
based combination therapies (ACTs) and insecticide-
treated nets (ITNs); more than 900 million ITNs have
been distributed in sub-Saharan African countries in the
last ten years [2]. However, this does not mean that the
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mission has been accomplished [3]. Increasing malaria
resistance to non-artemisinin partner drugs is alarming
and necessitates rapid action in order to maintain
frontline ACTs [4]. The emergence and spread of arte-
misinin resistance as well as the failure of its contain-
ment across Southeast Asia may reverse the significant
advances made in falciparum malaria control thus far
[5–7]. It is noteworthy that ACT- and ITN-based inter-
ventions may result in the infectious reservoir in low-
transmission settings to be predominantly submicro-
scopic [8]. Consequently, efforts should be dedicated to
detecting submicroscopic drug-resistant parasite popu-
lations in regions that are low-transmission settings
and/or in pre-elimination phases. Combating malaria
should be oriented towards the realization of the Sus-
tainable Development Goal of the UN to “ensure
healthy lives and promote well-being for all at all ages”
in endemic, resource-limited countries [9, 10], and such
control and elimination efforts must consider the hid-
den reservoir of resistant parasites.
With the absence of a clinically effective vaccine
against malaria [11–13], prompt diagnosis and timely
treatment with efficacious antimalarial drugs is still one
of the principal mainstays of malaria control and elim-
ination. The WHO recommends that treatment should
be given after diagnosis by microscopy or rapid diag-
nostic tests [14]. However, despite this process being
important for the prevention of severe malaria, treat-
ment of laboratory-confirmed malaria overlooks the
asymptomatic and submicroscopic malaria infections
that could potentially contribute to parasite transmis-
sion and the spread of drug resistance. The use of mass
drug administration (MDA) is still controversial as an
effective strategy for malaria elimination due to con-
cerns about the possibility of accelerating drug resist-
ance and faces a number of operational challenges,
including coverage, safety and monitoring its impact on
the rate of transmission [15]. In addition, it is difficult
to persuade everyone to take medications in MDA cam-
paigns when they are not sick. However, even if this ap-
proach was applied to a certain geographical area, there
still would be a need to assess the resistance situation
among residual submicroscopic parasites, taking into
account that partially effective treatment may leave re-
sistant parasites behind. Therefore, the present opinion
paper discusses this missing link of submicroscopic re-
sistant parasites that form a hidden reservoir of resist-
ance to antimalarial drugs that needs to be assessed for
possible role in persistent transmission. In addition, it
highlights the importance of assessing its magnitude
and potential in hindering malaria elimination, particu-
larly in areas of low transmission or in pre-elimination
phase, to take the necessary steps in order to interrupt
the spread of malaria and antimalarial drug resistance.
Discussion
The hidden reservoir of resistance to antimalarial drugs
refers to the submicroscopic reservoir of resistant mal-
aria parasites that usually circulate in low-endemicity
settings, particularly the residual parasites remaining
after treatment. One of the greatest challenges that hin-
ders malaria elimination in areas of low-transmission or
in those entering the pre-elimination phase is the re-
sidual Plasmodium falciparum parasites that are often
submicroscopic, partly because of drug resistance, par-
ticularly in areas where artemisinin-resistant parasites
have emerged. Intuitively, submicroscopic malaria infec-
tions are resistant so that they can persist in such situa-
tions. Most clinical and epidemiological studies on
antimalarial drug resistance have focused on microscop-
ically patent infections, which makes it difficult to deter-
mine the true burden of resistance in pre-elimination
and elimination settings, as this approach ignores the
hidden reservoir of submicroscopic resistant P. falcip-
arum genotypes in surveillance studies for the detection
of molecular markers of resistance. This is of paramount
importance as residual resistant parasites could contrib-
ute to the risk of further malaria transmission, or even
be the cause of a resurgence or spread of malaria.
Reservoir of submicroscopic malaria infection and
resistant parasites: the need to shift gears from
sensitive to ultra-sensitive detection
The detection of drug resistance in submicroscopic
malaria infections requires the development of ultra-
sensitive molecular techniques. The nested polymerase
chain reaction (PCR), which amplifies 18S rRNA, has
a detection limit of six parasites/μl of blood from dried
spots blotted onto filter papers [16]. Molecular assays that
have been developed more recently have a detection limit
of 0.02 parasite/μl (by quantitative PCR) and 0.01 para-
site/μl (by quantitative nucleic acid sequence-based ampli-
fication assays) [17]. The field-applicable loop-mediated
isothermal amplification (LAMP) has a detection limit of
0.1–2 parasites/μl [17, 18]. Although molecular techniques
can be used in retrospective epidemiological surveys as
they involve the collection of blood samples on filter
paper, these methods use small volumes of finger-prick ca-
pillary blood (usually 5 μl), which limit their detection po-
tential in very low parasite densities. Supposing that a
technique could amplify nucleic acids from a single para-
site, its sensitivity would still be limited due to the small
sample volume (one parasite per 5 μl) and it could not
detect parasite densities of <200 parasites/ml [19].
Generally, the detection limit of using finger-prick capil-
lary blood is 1 000 or more parasites per ml [19]. To ad-
dress this challenge, quantitative real-time PCR methods
using increased venous blood volumes (0.5–1.0 ml) have
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been developed and validated to detect parasite densities
as low as 20–22 parasites/μl [19, 20].
Interruption of malaria transmission through MDA or
mass screen-and-treat strategies necessitates the develop-
ment of next generation rapid diagnostic tests that can de-
tect the lowest threshold of infectiousness of human
populations to vector mosquitoes [21]. In epidemiological
surveys assessing the effectiveness of elimination strat-
egies, information derived from pooled sampling should
also be considered for active case detection in low-
transmission or pre-elimination areas to enable conduct-
ing large-scale surveys at a reasonable time and a reduced
cost of molecular investigations in resource-limited coun-
tries. This approach has been proven to be cost-effective
in surveillance studies, particularly when combined with
real-time PCR [22–25]. However, molecular techniques
that use high blood volumes are not suitable for large-
scale surveillance studies due to logistic difficulties to col-
lect and store venous blood under field conditions in trop-
ical climates, compared to the more convenient collection
storage and transport of small-volume dried blood spots
on filter papers. Therefore, novel, field-deployable point-
of-care approaches that combine blood pooling, samples
of high blood volumes and LAMP should be developed
and validated for the sensitive detection of submicroscopic
malaria infections and for the characterization of drug re-
sistance among parasite populations.
Submicroscopic reservoir of resistant parasites:
the missing link in malaria elimination strategies
Surveillance studies that examine antimalarial drug resist-
ance are mostly concerned with the identification and val-
idation of molecular markers of resistance in patients with
laboratory-confirmed malaria [26], but disregard the de-
tection of submicroscopic malaria infections. It is well
documented that there are many more masked or hidden
human infectious reservoirs in endemic areas than what
can be detected by microscopy, and these reservoirs can
contribute to maintaining malaria transmission and result
in drug resistance emergence and/or spread [27–29]. Par-
asites resistant to antimalarial drugs and vectors resistant
to insecticides are biological threats to malaria elimination
[30–32]. This is why there are increasing concerns about
the emergence and spread of artemisinin resistance in
Southeast Asia, with the possibility of its spread to India
and Africa [7], as this could possibly reduce the effective-
ness of ACT interventions. Another concern is the dor-
mancy, or temporarily arrested growth, of P. falciparum
parasites that leads to some degree of tolerance to artemi-
sinins [33–35]. This too may facilitate the emergence of
parasite resistance to ACTs [34–36].
It is estimated that submicroscopic carriers are a
source of 20–50% of all human-to-mosquito transmis-
sions at very low levels of transmission [37], where
submicroscopic gametocyte densities as low as <5 ga-
metocytes/μl of blood can induce mosquito infections
[27]. Early studies have shown that humans with micro-
scopically undetectable gametocytes are infectious to
mosquitoes, and that gametocyte and non-gametocyte
carriers contribute to the infectious reservoir for malaria
[38, 39]. Molecular techniques reveal that submicroscopic
gametocytaemia is common after treatment [40], and such
submicroscopic levels have been documented to contrib-
ute to mosquito infections after treatment with ACTs
[41]. The question remains as to what extent submicro-
scopic infections contribute to the emergence and spread
of resistance to antimalarial drugs, particularly in areas of
low transmission. In such a context, it has been suggested
that submicroscopic gametocytes following antimalarial
treatment could be a possible marker of resistant parasites
[42]. The magnitude and role of submicroscopic infections
that are drug-resistant remain unknown. In surveillance
studies, detection of submicroscopic reservoir of P. falcip-
arum parasites is usually not accompanied by the estima-
tion of the proportion of resistant parasite genotypes
within this parasite population which may contribute to
both malaria transmission and spread of antimalarial drug
resistance. Together with other measures, it is of utmost
importance to assess the hidden reservoir of resistant par-
asites and subsequently tailor suitable interventions for
targeting it. Drug-resistant parasites persisting in a zone
with continuous drug pressure have biological advantages
that enhance infection and transmission, including better
survival, increased proliferation of asexual erythrocyte
stages and increased gametocyte transmissibility, com-
pared to drug-sensitive parasites [43].
Several surveillance studies have used strategies such
as detecting molecular markers of resistance among
parasite isolates from malaria patients found positive by
microscopy or from nucleic acids extracted from rapid
diagnostic tests to study antimalarial drug resistance
[44–46]. However, these approaches neglect the contri-
bution of submicroscopic malaria infections to the reser-
voir of resistant parasites. Mathematical modeling
predicts that mass screen-and-treat strategies can be
successful in increasing the number of regions that can
interrupt malaria transmission from an entomological
inoculation rate of <1 to 1–4, if the diagnostic sensitivity
increases from 200 to 2 parasites/μl [21].
Given that about half of all P. falciparum infections are
not detected by microscopy in endemic areas [47], the
drug-resistant parasite population is substantially underes-
timated. Although some studies have detected molecular
markers of resistance after molecular diagnosis of P. fal-
ciparum malaria [48], this process is not routinely per-
formed as part of surveillance systems in pre-defined
sentinel sites. In addition, it ignores the detection of mo-
lecular markers in submicroscopic infections. The relative
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contribution of both microscopic and submicroscopic
malaria infections to the total parasite population that are
drug-resistant in a given area should be determined by
tracking molecular markers of resistance in both types of
infections. Such an integrated approach will determine the
ratio of markers in submicroscopic infections to those in
microscopic infections, through which the relative contri-
bution of the submicroscopic reservoir of resistance to the
total drug-resistant parasite populations in an endemic
setting could be identified. Of particular importance is
measuring the contribution of artemisinin resistance, as
alternative drugs that can undertake artemisinin’s role in
combination therapies are yet to be developed. Although
several antimalarial drug candidates are in the pipeline to
replace artemisinin, most are still being developed in ex-
ploratory clinical trials [49, 50].
Mapping the prevalence of molecular markers of drug-
resistant malaria, particularly artemisinin derivatives, in
submicroscopic and microscopic infections in endemic
areas is urgently needed. The recent discovery of a mo-
lecular marker of artemisinin resistance due to muta-
tions in the kelch gene K13 [51] could facilitate the
mapping of resistance at its molecular level in submicro-
scopic and microscopic falciparum malaria before these
infections become clinically evident. The containment of
artemisinin resistance through enhanced and sustained
surveillance of resistant parasites should be given top
priority [52]. In addition, the novel epidemiological tool
Focused Screening and Treatment has been recently in-
troduced for active molecular detection, treatment and
tracking of asymptomatic parasite carriers to counteract
the spread of drug-resistant parasites [53]. This supports
the need for the development and validation of new
tools that can effectively detect and track submicro-
scopic foci of resistant parasites in areas approaching
malaria elimination. Interventions for malaria elimin-
ation can thus be based on evidence-based knowledge of
the relative contribution of submicroscopic malaria in-
fections to the total reservoir of resistant parasites.
Molecular surveillance of resistance markers, which
is mostly based on the detection of parasites in micro-
scopic infections, should be extended to detection and
characterization of submicroscopic infections in future
strategies for malaria elimination. This will shift the sur-
veillance of antimalarial drug resistance from reactive to
proactive actions. Therefore, if resistance emerges in a de-
fined geographical area, even at the submicroscopic level,
appropriate interventions can be undertaken to eliminate
the detected foci of resistance. For example, the gametocy-
tocidal drug primaquine could be administered to the
population in that area, according to the updated recom-
mendation of the WHO’s Malaria Policy Advisory Com-
mittee, in order to block the transmission of both drug-
sensitive and drug-resistant parasites to vectors [54].
Conclusions
The integrated tracking of molecular markers of resistance
in submicroscopic and microscopic malaria infections
could enhance the detection of emerging drug resistance,
as well as identify the “true” burden of resistant parasites
in settings that have different malaria endemicities.
Surveillance studies that examine the hidden reservoir of
resistant parasites in low-transmission settings should en-
hance their sensitive detection methods; first, extracting
the parasite’s nucleic acids from a large amount of blood
(0.5–3 ml), followed by detection using ultra-sensitive
real-time PCR [55]. Of equal importance is the detection
and monitoring of reservoirs of submicroscopic resistant
parasites in sentinel sites in malaria-endemic areas. In
addition, the contribution of these reservoirs to the spread
of malaria transmission and drug resistance in such set-
tings should be determined in the context of malaria elim-
ination efforts. Steps should also be taken to develop new
highly-sensitive, field-applicable molecular approaches for
detecting resistant parasite genotypes responsible for sub-
microscopic infections.
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